Plant ID: NPO29004
Plant Latin Name: Ruta pinnata
Taxonomy Genus: Ruta
Taxonomy Family: Rutaceae
NCBI TaxonomyDB:
452794
Plant-of-the-World-Online:
775133-1
China
FFAR1; FFAR4; | |
NPSR1; | |
ALPL; ALOX12; HSD17B2; HSD17B10; ALOX15; NOX4; APEX1; POLB; | |
ACHE; | |
BCL2; | |
KDR; MET; AXL; FLT3; CDK1; PIM1; CDK6; PRKCA; IGF1R; AURKB; | |
CA2; CA12; CA1; CA14; CA7; | |
PPARA; | |
NR1H4; | |
TYR; | |
KDM4E; | |
F10; | |
AHR; NFKB1; | |
FUT7; | |
SLCO1B1; | |
LMNA; FABP3; FABP5; FABP4; MAPT; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.610E-10 | 5.009E-07 | CA1, CA12, CA14, CA2, CA7 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 4.601E-08 | 3.847E-05 | ALOX12, AURKB, AXL, BCL2, CDK1, FFAR4, IGF1R, KDR, LMNA, NFKB1, NR1H4, PIM1, PRKCA |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.538E-08 | 4.307E-05 | CA1, CA12, CA14, CA2, CA7 |
BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 2.060E-07 | 1.137E-04 | ACHE, CYP1A1, CYP1B1, FFAR1, FFAR4, HSD17B2, NFKB1, NR1H4, PRKCA, SLCO1B1 |
MF | GO:0005488; binding | GO:0005504; fatty acid binding | 4.337E-07 | 1.927E-04 | FABP3, FABP4, FABP5, FFAR4 |
BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 1.154E-06 | 4.079E-04 | ALOX12, BCL2, CA12, CA2, CA7, FABP3, FABP4, FFAR1, MET, NOX4, NPSR1, NR1H4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.402E-06 | 4.653E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.433E-06 | 4.653E-04 | CA1, CA12, CA2, CA7 |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 2.191E-06 | 6.362E-04 | ALPL, APEX1, BCL2, CA2, CYP1A2, FABP3, FFAR4, FLT3, NFKB1, PPARA |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 3.514E-06 | 9.565E-04 | ACHE, ALOX15, BCL2, CDK1, CYP1A1, PPARA |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.571E-06 | 9.599E-04 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 4.893E-06 | 1.216E-03 | ALOX12, ALOX15, APEX1, CYP1A1, CYP1A2, CYP1B1, HSD17B10, HSD17B2, KDM4E, NOX4, TYR |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 5.307E-06 | 1.216E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.307E-06 | 1.216E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.307E-06 | 1.216E-03 | ALOX12, ALOX15 |
BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 7.237E-06 | 1.641E-03 | ALOX12, BCL2, F10, IGF1R, KDR, MET, NOX4, PRKCA |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 7.853E-06 | 1.763E-03 | AURKB, CDK1, PRKCA |
BP | GO:0008152; metabolic process | GO:0070988; demethylation | 1.065E-05 | 2.230E-03 | APEX1, CYP1A1, CYP1A2, KDM4E |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.217E-05 | 2.486E-03 | APEX1, AXL, CDK1, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.526E-05 | 2.909E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.544E-05 | 2.909E-03 | ALPL, APEX1, CYP1A1, CYP1B1, FLT3, NFKB1, NOX4 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.590E-05 | 2.909E-03 | CA2, CA7 |
BP | GO:0019740; nitrogen utilization | GO:0006808; regulation of nitrogen utilization | 1.590E-05 | 2.909E-03 | BCL2, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.590E-05 | 2.909E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.590E-05 | 2.909E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.025E-05 | 3.557E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.025E-05 | 3.557E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.622E-05 | 4.361E-03 | FABP3, FABP4, FABP5 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.175E-05 | 5.042E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.424E-05 | 5.295E-03 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0016572; histone phosphorylation | 3.716E-05 | 5.698E-03 | AURKB, CDK1, PRKCA |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 4.196E-05 | 6.354E-03 | ALPL, AXL, CYP1A1, CYP1A2, NFKB1, NR1H4 |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 5.283E-05 | 7.422E-03 | ALOX12, ALOX15 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 5.590E-05 | 7.704E-03 | AHR, KDR, MAPT |
MF | GO:0005488; binding | GO:0008134; transcription factor binding | 5.742E-05 | 7.864E-03 | AHR, APEX1, BCL2, FLT3, NFKB1, NR1H4, PIM1, PPARA |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 7.013E-05 | 9.145E-03 | AXL, FLT3, IGF1R, KDR, MET |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.780E-10 | 4.226E-08 | CA12, CA1, CA2, CA7, CA14 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.774E-06 | 2.419E-04 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.153E-06 | 2.419E-04 | CDK6, PIM1, BCL2, CYP1B1, PRKCA, MET, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.024E-05 | 3.113E-04 | CDK6, KDR, BCL2, PRKCA, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.727E-05 | 5.922E-04 | CDK6, FLT3, BCL2, PRKCA, MET, NFKB1, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 8.681E-06 | 3.113E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 7.786E-05 | 1.338E-03 | PIM1, BCL2, PRKCA, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.737E-05 | 4.401E-04 | FABP3, FABP4, FABP5, PPARA |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 8.800E-05 | 1.338E-03 | KDR, BCL2, PRKCA, MET, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 8.403E-05 | 1.338E-03 | BCL2, PRKCA, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.521E-04 | 1.927E-03 | KDR, PRKCA, MET, NFKB1, IGF1R |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 9.921E-05 | 1.371E-03 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 3.218E-04 | 3.494E-03 | CDK6, BCL2, PRKCA, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.861E-04 | 3.345E-03 | FLT3, PIM1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 4.217E-04 | 4.273E-03 | CDK6, PRKCA, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 5.467E-04 | 4.888E-03 | CDK6, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.109E-03 | 7.280E-03 | KDR, PRKCA, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 7.088E-04 | 5.671E-03 | FLT3, MET, NFKB1, IGF1R |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 5.467E-04 | 4.888E-03 | SLCO1B1, CA2, NR1H4 |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.150E-03 | 7.280E-03 | POLB, CDK6, CDK1, NFKB1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.930E-04 | 5.008E-03 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.056E-03 | 7.280E-03 | BCL2, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.279E-03 | 7.774E-03 | KDR, PRKCA, MET, IGF1R |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.525E-03 | 8.913E-03 | FUT7, HSD17B2, CYP1A2, ALOX15, CYP1A1, ALPL, ALOX12, TYR, HSD17B10 |
09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 9.561E-04 | 6.920E-03 | CDK6, BCL2, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.325E-04 | 6.327E-03 | CYP1A2, CYP1A1, CYP1B1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
NA: NA | HIV infections | NA | AHR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; BCL2; |
NA: NA | Edema | NA | CA2; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
NA: NA | GIST | NA | FLT3; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
NA: NA | Christmas disease | NA | F10; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; BCL2; |
I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; BCL2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; F10; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; BCL2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA2; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; ACHE; CA1; BCL2; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; |
I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; |
I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; MAPT; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
NA: NA | Haemophilia B | NA | F10; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | BCL2; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; CA1; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; BCL2; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |